Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About Singular Genomics Systems, Inc.
Singular Genomics Systems Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in San Diego, California and currently employs 255 full-time employees. The company went IPO on 2021-05-27. Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The firm has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The firm is also engaged in developing PX, which is a development-stage multiomics platform.
Industry: Laboratory Analytical Instruments Peers: Absci Corp Alpha Teknova, Inc. Nautilus Biotechnology, Inc. Bruker Cellular Analysis, Inc. CHAMPIONS ONCOLOGY, INC. Science 37 Holdings, Inc. Personalis, Inc. Quanterix Corp RAPID MICRO BIOSYSTEMS, INC. THERMO FISHER SCIENTIFIC INC.
